The virus that has claimed nearly 3,500 lives around the world is spread via gut bacteria, a new study suggests.
Researchers from the University of California, Davis, looked at the viral proteins that are made by a range of bacteria in the intestines and found that the virus could not only be passed through the intestinal tract but also spread through the blood stream, making it even more difficult to control.
The study is published in the journal Science.
The researchers used a virus called the novel coronavirus (NCV) that has emerged in recent years in people from Africa, Asia, and Europe.
NCV is believed to have been responsible for a surge in deaths in many parts of the world.
In the new study, they used a strain of NCV that had been created by scientists in Japan to examine how the virus spreads and how it causes inflammation in the body.
“The ability to spread this virus is quite a remarkable ability,” said study lead author and University of Cali, Davis Professor of Pathology and Microbiology, Dr. Jürgen Rehm.
“This study shows that it is possible to use the gut bacteria to transmit the virus, but that we have to do so in a way that will not kill the host.”
The new study is the first to examine the gut microbiome and its role in the spread of a viral infection.
They found that while the virus may have its origin in the human gut, it is passed in a much more efficient way through the gut than through the respiratory tract, meaning it is much more difficult for the host to stop.
Researchers believe that the human body is able to create antibodies that can fight off the virus.
But the human immune system is limited and cannot fight against the virus itself.
To address this, the researchers created a strain that could use the same bacteria as the human host to fight the virus and pass it to other animals.
This means that the vaccine can be delivered to other mammals as well.
“This is a huge advancement for the field,” said Dr. Rehm, who was also a member of the team that first isolated human and mouse antibodies against the NCV.
He added that this work opens up the possibility of using the human-to-animal vaccine in the future.
The findings are the result of a study that was funded by the National Institutes of Health.
The study was conducted at the UC Davis Vaccine Center and the Center for Human Microbiome and Microbial Evolution at the University at Buffalo.
The researchers say the work will have implications for the future of vaccine development.
While they have not been able to determine how the human and the mouse antibodies work, they are certain that the antibodies are able to kill the virus from the human to the animal.
“The human antibody is able of killing the virus as well,” Dr. Hsu said.
“It is also a great achievement to be able to see this through the eyes of the human being.”
The work has some scientific implications for vaccine development, said Dr Rehm: “We know that there are human antibodies that have the ability to fight Ebola, but the human antibody does not have that capability yet.”
“We think that our next steps will be to try to develop a human antibody that can actually target the virus,” he said.
“Then, we would then want to see if we can develop a vaccine to fight this disease in humans.”
For more on this story, watch the video below: